← Browse by Condition
Medical Condition
carcinoma non small cell lung
Total Trials
11
Recruiting Now
11
Trial Phases
Phase 2, Phase 3, Phase 4
NCT06001151 Phase 2
Recruiting
Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative
Enrollment
49 pts
Location
China
Sponsor
Qian Chu
NCT07161882
Recruiting
ALG-LungCancerRegistry (SAFRO2202)
Enrollment
3,750 pts
Location
Algeria
Sponsor
Société Algérienne de Formatio...
NCT03586453 Phase 2
Recruiting
Osimertinib In EGFR Mutant Lung Cancer
Enrollment
30 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
NCT05805631 Phase 2
Recruiting
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
Enrollment
23 pts
Location
Taiwan
Sponsor
Taipei Veterans General Hospit...
NCT06269211 Phase 2
Recruiting
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
Enrollment
29 pts
Location
China
Sponsor
Ruijin Hospital
NCT06008093 Phase 3
Recruiting
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Enrollment
280 pts
Location
United States
Sponsor
AstraZeneca
NCT05525338 Phase 4
Recruiting
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
Enrollment
196 pts
Location
France, Netherlands
Sponsor
University Medical Center Gron...
NCT05768178 Phase 2, Phase 3
Recruiting
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
NCT06566443 Phase 1
Recruiting
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
Enrollment
15 pts
Location
United States
Sponsor
The Methodist Hospital Researc...
NCT06380816 Phase 1, Phase 2
Recruiting
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Enrollment
167 pts
Location
United Kingdom
Sponsor
Cancer Research UK
NCT06667076 Phase 2
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Enrollment
480 pts
Location
United States, Belgi...
Sponsor
Janssen Research & Development...